SOURCE: Cutting Edge Information

Cutting Edge Information

December 01, 2015 11:01 ET

Pharmaceutical Companies Look to Health Outcomes Liaisons to Disseminate Health Economics and Outcomes Data to Payer Organizations

RESEARCH TRIANGLE PARK, NC--(Marketwired - December 01, 2015) - According to a health economics and outcomes research (HEOR) report by primary intelligence firm Cutting Edge Information, surveyed teams dedicate the largest headcount to HEOR analysts -- the essential team members responsible for collecting and working with pharmacoeconomic data. However, the role of health outcomes liaisons (HOLs) grows in importance as pharmaceutical companies are under increasing pressure to provide a full value story to payers that answers outcomes, pharmacoeconomic and budgetary questions.

Top 10 and 50 companies' EU and global HEOR teams report the highest headcount for HEOR analysts -- at an average 15 and 13.8 full-time equivalents (FTEs), respectively. HOLs claim the second highest headcount at surveyed Top 10 and Top 50 companies' global and U.S. teams -- at an average 7 and 5 FTEs, respectively.

HOLs take on the task of disseminating compelling HEOR data to payer organizations and other stakeholders. As such, pharma and device companies must consider a number of factors when determining HOL headcount, including customer base, product portfolio and support brands, and team budgets.

"Though life science companies may rely on medical science liaisons or commercial reps to maintain regular contact with stakeholders, HOLs have a strong grasp of the organization's HEOR data due to the nature of their role," said Jacob Presson, senior research analyst at Cutting Edge Information. "To ensure that key payers receive the best possible presentations of these data, many companies -- especially those with small HEOR groups -- are looking to expand their HOL headcounts."

Building World-Class HEOR Teams: Creating Convincing Value Proposition for Payers, available at, highlights HEOR group structure, staffing and spending at pharmaceutical and medical device companies around the world. The report's resource metrics allow health economics groups to benchmark their activities against the rest of the industry and to ensure that they are effectively supporting their products. Highlights include:

  • Benchmarks showing HEOR spending from 2013 to 2015 per company and on a per-product basis
  • Data showing HEOR group oversight, leadership and funding sources
  • Executive perspectives on demonstrating the value of HEOR internally
  • Insights on how to ensure that stakeholders beyond payers are understood when developing health economics research

For other market access topics, view Cutting Edge Information's market access library at

Image Available:

Contact Information